FindTrial
Sign In

Prospective Pilot study of Infliximab Dose-intensification determined by Capsule Endoscopic Evaluation of Small Intestinal Involvements in Patients with Crohn's Disease

Prospective Pilot study of Infliximab Dose-intensification determined by Capsule Endoscopic Evaluation of Small Intestinal Involvements in Patients with Crohn's Disease - CADELLAC study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012790
Enrollment
20
Registered
2014-02-01
Start date
2014-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

dose intensification of 10mg/kg infliximab with additional treatment with thiopurines in case of aggravation at 6 months

Sponsors

Saitama Medical center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 6 months steroid free CD patients with CDAI which was no more than 150

Exclusion criteria

Exclusion criteria: patients with contraindication of infliximab patients with pregnancy and lactation patients without informed consent patients under and after treatment of malignancy

Design outcomes

Primary

MeasureTime frame
mucosal healing rates at 6 months—

Secondary

MeasureTime frame
mucosal healing rates at 12 months improvement of mucosal regions at 6 and 12 months serum CRP titer at 6 and 12 months stool calprotectin titer at 6 and 12 months stool PTX3 titer at 6 and 12 months safety—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical center Department of gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026